1. Home
  2. NTLA vs COHU Comparison

NTLA vs COHU Comparison

Compare NTLA & COHU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • COHU
  • Stock Information
  • Founded
  • NTLA 2014
  • COHU 1947
  • Country
  • NTLA United States
  • COHU United States
  • Employees
  • NTLA N/A
  • COHU N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • COHU Electrical Products
  • Sector
  • NTLA Health Care
  • COHU Industrials
  • Exchange
  • NTLA Nasdaq
  • COHU Nasdaq
  • Market Cap
  • NTLA 1.2B
  • COHU 1.0B
  • IPO Year
  • NTLA 2016
  • COHU N/A
  • Fundamental
  • Price
  • NTLA $12.27
  • COHU $24.06
  • Analyst Decision
  • NTLA Buy
  • COHU Buy
  • Analyst Count
  • NTLA 20
  • COHU 6
  • Target Price
  • NTLA $25.83
  • COHU $28.20
  • AVG Volume (30 Days)
  • NTLA 9.7M
  • COHU 846.9K
  • Earning Date
  • NTLA 11-06-2025
  • COHU 10-29-2025
  • Dividend Yield
  • NTLA N/A
  • COHU N/A
  • EPS Growth
  • NTLA N/A
  • COHU N/A
  • EPS
  • NTLA N/A
  • COHU N/A
  • Revenue
  • NTLA $52,857,000.00
  • COHU $393,941,000.00
  • Revenue This Year
  • NTLA $9.20
  • COHU $13.76
  • Revenue Next Year
  • NTLA N/A
  • COHU $12.59
  • P/E Ratio
  • NTLA N/A
  • COHU N/A
  • Revenue Growth
  • NTLA 14.99
  • COHU N/A
  • 52 Week Low
  • NTLA $5.90
  • COHU $12.57
  • 52 Week High
  • NTLA $28.25
  • COHU $29.42
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 32.04
  • COHU 60.81
  • Support Level
  • NTLA $13.21
  • COHU $21.23
  • Resistance Level
  • NTLA $26.35
  • COHU $22.98
  • Average True Range (ATR)
  • NTLA 1.91
  • COHU 0.96
  • MACD
  • NTLA -1.94
  • COHU 0.20
  • Stochastic Oscillator
  • NTLA 3.07
  • COHU 68.06

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About COHU Cohu Inc.

Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection).

Share on Social Networks: